PPMD Annual Conference to Feature Three Late-Breaking News Sessions

We are excited to announce that three industry partners will be presenting updates to the Duchenne community in late–breaking news sessions during PPMD’s 2022 Annual Conference, June 23-26 in Scottsdale, AZ.

Partners that will be presenting newly released data and/or program updates are: Capricor Therapeutics, Italfarmaco, and PTC Therapeutics.

Capricor Therapeutics

Dr. Linda Marbán, CEO of Capricor Therapeutics, will present 1-year efficacy results from the ongoing HOPE-2 open label extension study of CAP-1002 in non-ambulant Duchenne patients on Saturday, June 25 at 5:05 PM PT.

Italfarmaco

Dr. Paolo Bettica, Chief Medical Officer at Italfarmaco, will present the Givinostat Phase III Study results from the EpiDys trial in ambulant patients with Duchenne on Saturday, June 25 at 4:45 PM PT.

PTC Therapeutics

Dr. Matthew Klein, Chief Operating Officer at PTC Therapeutics, will present an update on the development of ataluren on Friday, June 24 at 12:10 PM PT.

Additional Sessions

In addition to these presentations, PPMD’s 2022 Annual Conference will feature dedicated updates from 20 industry partners currently in clinical trials, with panel sessions including:

• Gene Therapy Approaches to Replace or Restore Dystrophin
• Strategies for Mitigating Inflammation and Fibrosis
• Restoring Dystrophin via Exon Skipping Strategies
• Novel Approaches for Combating Duchenne
• Emerging Therapies for Becker Muscular Dystrophy

If you haven’t registered for PPMD’s 2022 Annual Conference — what are you waiting for? Check out our full agenda and register to join us virtually or in-person!

Register Today >